Literature DB >> 27644574

Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital.

Hirokazu Ogino1, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Makoto Tobiume, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa, Yasuhiko Nishioka.   

Abstract

BACKGROUND: Small-cell lung cancer (SCLC) presents aggressive clinical behavior, and its prognosis is still poor. Previously, performance status (PS), or the existence of brain, bone, or liver metastasis were reported to be unfavorable prognostic factors. Given the recent progress of treatment modalities such as radiotherapy techniques and bone modifying agents, the prognostic factors might be different from previous findings. Therefore, we analyzed the prognostic factors of extensive disease SCLC (ED-SCLC) in recent years.
METHODS: ED-SCLC patients treated in Tokushima University Hospital between 2010 and 2016 were analyzed. Log-rank test and the Cox proportional hazards regression model was used in univariate and multivariate analysis, respectively.
RESULTS: Totally, 79 patients were analyzed. In the univariate analysis, age, PS, interstitial pneumonia (IP), liver metastasis, pleural dissemination, neutrophil counts, hypoalbuminemia, hypercalcemia and several liver and biliary enzymes were identified as poor prognostic factors. In the multivariate analysis, age, PS, IP, and liver and biliary enzymes were identified. Moreover, the PS in patients with liver metastasis was significantly worsened.
CONCLUSIONS: In this study, we newly demonstrated that IP was a significant poor prognostic factor of ED-SCLC. Although liver metastasis was not extracted in multivariate analysis, it may have an impact on the prognosis of ED-SCLC. J. Med. Invest. 63: 286-293, August, 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27644574     DOI: 10.2152/jmi.63.286

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  6 in total

1.  Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases.

Authors:  Atsushi Mitsuhashi; Yusuke Okuma; Yoshitaka Zenke; Yukio Hosomi
Journal:  Mol Clin Oncol       Date:  2018-09-04

2.  A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.

Authors:  Zhengang Qiu; Anqi Lin; Kun Li; Weiyin Lin; Qiongyao Wang; Ting Wei; Weiliang Zhu; Peng Luo; Jian Zhang
Journal:  Drug Des Devel Ther       Date:  2019-06-21       Impact factor: 4.162

3.  Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients.

Authors:  Damian von Eiff; Farastuk Bozorgmehr; Inn Chung; Denise Bernhardt; Stefan Rieken; Stephan Liersch; Thomas Muley; Sonja Kobinger; Michael Thomas; Petros Christopoulos; Martin Steins
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

4.  CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Yonglin Yi; Zhengang Qiu; Zifu Yao; Anqi Lin; Yimin Qin; Ruizhan Sha; Ting Wei; Yanru Wang; Quan Cheng; Jian Zhang; Peng Luo; Weitao Shen
Journal:  Front Cell Dev Biol       Date:  2022-01-11

5.  DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer.

Authors:  Man Li; Anqi Lin; Peng Luo; Weitao Shen; Dan Xiao; Lanying Gou; Jian Zhang; Linlang Guo
Journal:  Aging (Albany NY)       Date:  2020-01-20       Impact factor: 5.682

6.  High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.

Authors:  Qiong Lyu; Weiliang Zhu; Ting Wei; Weimin Ding; Manming Cao; Qiongyao Wang; Linlang Guo; Peng Luo; Jian Zhang
Journal:  Cancer Med       Date:  2021-09-26       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.